3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Genitourinary
2
Lymphoid
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Rituximab
377
Cyclophosphamide
180
Bendamustine Hydrochloride
110
obinutuzumab
100
Vincristine
95
fludarabine
92
Prednisone
90
Doxorubicin
90
ibrutinib
89
venetoclax
86
Lenalidomide
82
Gemcitabine
65
acalabrutinib
48
Brentuximab Vedotin
44
pembrolizumab
43
zanubrutinib
41
Dexamethasone
41
idelalisib
37
ofatumumab
32
Oxaliplatin
30
Chlorambucil
29
polatuzumab vedotin
25
blinatumomab
25
tocilizumab
24
Azacitidine
24
Prednisolone
23
tositumomab I-131
22
tisagenlecleucel
21
glofitamab
21
Nivolumab
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Inosine Monophosphate
×
Lymphoid
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled